Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder

Keming Gao, David E. Kemp, Stephen J. Ganocy, David J. Muzina, Guohua Xia, Robert L. Findling, Joseph R. Calabrese

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: To study treatment-emergent mania/hypomania (TEM) associated with second-generation antidepressant monotherapy in patients with rapid cycling bipolar disorder (RCBD). Methods: Data of patients with RCBD (n=180) enrolled into two clinical trials were used to study the risk for TEM during second-generation antidepressant monotherapy. History of TEM was retrospectively determined at the initial assessment by asking patients whether they were exposed to second-generation antidepressants and if a hypomania/ mania episode emerged during the first fourweeks of treatment. Data were analyzed using t-test, chi-square, and logistic regression. Results: Ofthe 180 patients (bipolar I disorder, n = 128; bipolar II disorder, n = 52) with RCBD, 85% (n = 153) had at least one antidepressant treatment. Among these patients, 94.1% (144/153) had at least one antidepressant monotherapy treatment. Overall, 49.3% of patients had at least one TEM and 29.1% (116/399) of treatment trials were associated with TEM. In regression analysis, an inverse association between the number of mood episodes in the last 12 months and TEM was observed with an odds ratio of 0.9. However, gender, bipolar subtype, a lifetime history of comorbid anxiety disorder, substance use disorder, or psychosis, and age of mood disorder onset were not associated with TEM. For individual antidepressants, the rates of TEM varied from 42.1% for fluoxetine to 0% for fluvoxamine and mirtazapine. As a group, there was no difference between selective serotonin reuptake inhibitors and venlafaxine or bupropion in the incidence of TEM. Conclusions: Use of second-generation antidepressants as monotherapy in RCBD is accompanied by clinically relevant rates of TEM. Even in patients with RCBD, differential vulnerabilities to antidepressant TEM may exist.

Original languageEnglish (US)
Pages (from-to)907-915
Number of pages9
JournalBipolar Disorders
Volume10
Issue number8
DOIs
StatePublished - 2008

Fingerprint

Bipolar Disorder
Antidepressive Agents
Therapeutics
Fluvoxamine
Bupropion
Fluoxetine
Serotonin Uptake Inhibitors
Chi-Square Distribution
Anxiety Disorders
Mood Disorders
Psychotic Disorders
Substance-Related Disorders

Keywords

  • Antidepressant monotherapy
  • Anxiety disorder
  • Rapid cycling bipolar disorder
  • Substance use disorder
  • Treatment-emergent mania

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Gao, K., Kemp, D. E., Ganocy, S. J., Muzina, D. J., Xia, G., Findling, R. L., & Calabrese, J. R. (2008). Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disorders, 10(8), 907-915. https://doi.org/10.1111/j.1399-5618.2008.00637.x

Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. / Gao, Keming; Kemp, David E.; Ganocy, Stephen J.; Muzina, David J.; Xia, Guohua; Findling, Robert L.; Calabrese, Joseph R.

In: Bipolar Disorders, Vol. 10, No. 8, 2008, p. 907-915.

Research output: Contribution to journalArticle

Gao, Keming ; Kemp, David E. ; Ganocy, Stephen J. ; Muzina, David J. ; Xia, Guohua ; Findling, Robert L. ; Calabrese, Joseph R. / Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. In: Bipolar Disorders. 2008 ; Vol. 10, No. 8. pp. 907-915.
@article{3a21427f70c042bcb8ebeb4a4ed0eaf2,
title = "Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder",
abstract = "Objective: To study treatment-emergent mania/hypomania (TEM) associated with second-generation antidepressant monotherapy in patients with rapid cycling bipolar disorder (RCBD). Methods: Data of patients with RCBD (n=180) enrolled into two clinical trials were used to study the risk for TEM during second-generation antidepressant monotherapy. History of TEM was retrospectively determined at the initial assessment by asking patients whether they were exposed to second-generation antidepressants and if a hypomania/ mania episode emerged during the first fourweeks of treatment. Data were analyzed using t-test, chi-square, and logistic regression. Results: Ofthe 180 patients (bipolar I disorder, n = 128; bipolar II disorder, n = 52) with RCBD, 85{\%} (n = 153) had at least one antidepressant treatment. Among these patients, 94.1{\%} (144/153) had at least one antidepressant monotherapy treatment. Overall, 49.3{\%} of patients had at least one TEM and 29.1{\%} (116/399) of treatment trials were associated with TEM. In regression analysis, an inverse association between the number of mood episodes in the last 12 months and TEM was observed with an odds ratio of 0.9. However, gender, bipolar subtype, a lifetime history of comorbid anxiety disorder, substance use disorder, or psychosis, and age of mood disorder onset were not associated with TEM. For individual antidepressants, the rates of TEM varied from 42.1{\%} for fluoxetine to 0{\%} for fluvoxamine and mirtazapine. As a group, there was no difference between selective serotonin reuptake inhibitors and venlafaxine or bupropion in the incidence of TEM. Conclusions: Use of second-generation antidepressants as monotherapy in RCBD is accompanied by clinically relevant rates of TEM. Even in patients with RCBD, differential vulnerabilities to antidepressant TEM may exist.",
keywords = "Antidepressant monotherapy, Anxiety disorder, Rapid cycling bipolar disorder, Substance use disorder, Treatment-emergent mania",
author = "Keming Gao and Kemp, {David E.} and Ganocy, {Stephen J.} and Muzina, {David J.} and Guohua Xia and Findling, {Robert L.} and Calabrese, {Joseph R.}",
year = "2008",
doi = "10.1111/j.1399-5618.2008.00637.x",
language = "English (US)",
volume = "10",
pages = "907--915",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "8",

}

TY - JOUR

T1 - Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder

AU - Gao, Keming

AU - Kemp, David E.

AU - Ganocy, Stephen J.

AU - Muzina, David J.

AU - Xia, Guohua

AU - Findling, Robert L.

AU - Calabrese, Joseph R.

PY - 2008

Y1 - 2008

N2 - Objective: To study treatment-emergent mania/hypomania (TEM) associated with second-generation antidepressant monotherapy in patients with rapid cycling bipolar disorder (RCBD). Methods: Data of patients with RCBD (n=180) enrolled into two clinical trials were used to study the risk for TEM during second-generation antidepressant monotherapy. History of TEM was retrospectively determined at the initial assessment by asking patients whether they were exposed to second-generation antidepressants and if a hypomania/ mania episode emerged during the first fourweeks of treatment. Data were analyzed using t-test, chi-square, and logistic regression. Results: Ofthe 180 patients (bipolar I disorder, n = 128; bipolar II disorder, n = 52) with RCBD, 85% (n = 153) had at least one antidepressant treatment. Among these patients, 94.1% (144/153) had at least one antidepressant monotherapy treatment. Overall, 49.3% of patients had at least one TEM and 29.1% (116/399) of treatment trials were associated with TEM. In regression analysis, an inverse association between the number of mood episodes in the last 12 months and TEM was observed with an odds ratio of 0.9. However, gender, bipolar subtype, a lifetime history of comorbid anxiety disorder, substance use disorder, or psychosis, and age of mood disorder onset were not associated with TEM. For individual antidepressants, the rates of TEM varied from 42.1% for fluoxetine to 0% for fluvoxamine and mirtazapine. As a group, there was no difference between selective serotonin reuptake inhibitors and venlafaxine or bupropion in the incidence of TEM. Conclusions: Use of second-generation antidepressants as monotherapy in RCBD is accompanied by clinically relevant rates of TEM. Even in patients with RCBD, differential vulnerabilities to antidepressant TEM may exist.

AB - Objective: To study treatment-emergent mania/hypomania (TEM) associated with second-generation antidepressant monotherapy in patients with rapid cycling bipolar disorder (RCBD). Methods: Data of patients with RCBD (n=180) enrolled into two clinical trials were used to study the risk for TEM during second-generation antidepressant monotherapy. History of TEM was retrospectively determined at the initial assessment by asking patients whether they were exposed to second-generation antidepressants and if a hypomania/ mania episode emerged during the first fourweeks of treatment. Data were analyzed using t-test, chi-square, and logistic regression. Results: Ofthe 180 patients (bipolar I disorder, n = 128; bipolar II disorder, n = 52) with RCBD, 85% (n = 153) had at least one antidepressant treatment. Among these patients, 94.1% (144/153) had at least one antidepressant monotherapy treatment. Overall, 49.3% of patients had at least one TEM and 29.1% (116/399) of treatment trials were associated with TEM. In regression analysis, an inverse association between the number of mood episodes in the last 12 months and TEM was observed with an odds ratio of 0.9. However, gender, bipolar subtype, a lifetime history of comorbid anxiety disorder, substance use disorder, or psychosis, and age of mood disorder onset were not associated with TEM. For individual antidepressants, the rates of TEM varied from 42.1% for fluoxetine to 0% for fluvoxamine and mirtazapine. As a group, there was no difference between selective serotonin reuptake inhibitors and venlafaxine or bupropion in the incidence of TEM. Conclusions: Use of second-generation antidepressants as monotherapy in RCBD is accompanied by clinically relevant rates of TEM. Even in patients with RCBD, differential vulnerabilities to antidepressant TEM may exist.

KW - Antidepressant monotherapy

KW - Anxiety disorder

KW - Rapid cycling bipolar disorder

KW - Substance use disorder

KW - Treatment-emergent mania

UR - http://www.scopus.com/inward/record.url?scp=56349109980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349109980&partnerID=8YFLogxK

U2 - 10.1111/j.1399-5618.2008.00637.x

DO - 10.1111/j.1399-5618.2008.00637.x

M3 - Article

C2 - 19594506

AN - SCOPUS:56349109980

VL - 10

SP - 907

EP - 915

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 8

ER -